Sankyo Co. Newsletter
-
AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in phase 3 breast cancer study
02 May 2024 07:23 GMT
AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from …
-
[Latest] Global Breast Cancer Therapeutics Market Size/Share Worth USD 66.1 Billion by 2033 at a 6.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
06 May 2024 12:30 GMT
…
Takeda Pharmaceutical Company Limited
Daiichi Sankyo Company Limited
Eisai Co. Ltd …
-
Sequencing Considerations in the Third-Line Treatment of Metastatic Colorectal Cancer
03 May 2024 23:45 GMT
… Pharmaceuticals, Inc; Celularity Inc; Daiichi Sankyo Company Limited; Deciphera Pharmaceuticals, Inc …
-
A Decade of Progress: Advances in the Third-Line Treatment of Patients With Metastatic Colorectal Cancer
03 May 2024 23:45 GMT
… Pharmaceuticals, Inc; Celularity Inc; Daiichi Sankyo Company Limited; Deciphera Pharmaceuticals, Inc …
-
Participating Faculty: Metastatic Colorectal Cancer: Considerations for Treatment in the Third Line and Beyond
03 May 2024 23:45 GMT
… Pharmaceuticals, Inc; Celularity Inc; Daiichi Sankyo Company Limited; Deciphera Pharmaceuticals, Inc …
-
FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer
03 May 2024 14:07 GMT
… —funded by AstraZeneca and Daiichi Sankyo, the drug’s manufacturer—on …
-
Fierce Pharma Asia—Ono buys Deciphera for $2.4B; Novartis expands PeptiDream collab; WuXi Bio exits BIO 2024
03 May 2024 14:02 GMT
… breast cancer
AstraZeneca and Daiichi Sankyo said their Enhertu has beat …
-
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
02 May 2024 20:00 GMT
…
Evkeeza
3,275
212
Daiichi Sankyo
—
1,479
Total revenues
$ …
-
The top pharmaceutical companies by R&D expenditure
02 May 2024 09:09 GMT
… another strategic partnership with Daiichi Sankyo to develop ADCs.
However, Merck … collaborations, such as with Daiichi Sankyo. These collaborations are already yielding … FDA’s approval of Daiichi Sankyo and AstraZeneca’s ADC, Enhertu …
-
NEXLETOL (bempedoic acid) for the Treatment of Heterozygous Familial Hypercholesterolemia (HeFH), USA
02 May 2024 09:04 GMT
… agreement with pharmaceutical company Daiichi Sankyo Europe (DSE) to commercialise bempedoic … extended its partnership with Daiichi Sankyo to include more countries across …